Patrick Campbell

Circulating antinephrin autoantibodies identified as reliable biomarkers for MCD and primary FSGS, enhancing diagnostic precision and monitoring of nephrotic syndromes.

Data from ERA 24 builds on previous research examining the effect of SGLT2 inhibitors on hemoglobin levels among patients with chronic kidney disease.

Hear from Katharina Mayer, MD, and Georg Böhmig, MD, on the results of the phase 2 trial of felzartamab in patients with antibody-mediated rejection following kidney transplantation.

Atrasentan significantly reduces proteinuria in patients with IgA nephropathy, showing a 36.1% reduction compared to placebo at 36 weeks.

Study finds roxadustat effectively treats anemia in both dialysis-dependent and non-dialysis-dependent CKD patients.

Vlado Perkovic, MBBS, PhD, discusses the results of the FLOW trial and their implications for clinical practice at ERA 24.

New study finds SGLT2 inhibitors reduce proteinuria in IgA nephropathy, with greater initial eGFR dips predicting stronger treatment responses.

Semaglutide 1.0 mg reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease, according to the FLOW trial.

Increases in metabolic risk factors like high blood pressure and BMI have led to a 49.4% increase in global disability-adjusted life years from 2000 to 2021.

A recent study suggests that high ultraprocessed food consumption in preschool children is linked to increased cardiometabolic risk factors.

On May 20, 2024, the FDA announced the approval of 2 products as interchangeable biosimilars to aflibercept—the first products to receive such a designation from the FDA.

Use of dupilumab reduced exacerbations and improved lung function in COPD patients with type 2 inflammation.

Data from a meta-analysis of evinacumab trials reveal significant reductions in cholesterol and other lipid markers among patients with dyslipidemia.

Biologic therapy for psoriasis showed no significant impact on cardiovascular risk factors over one year in a retrospective study from Australia.

Study finds 2013 ACC/AHA guideline led to immediate improvements in optimal statin use for ASCVD patients and enhanced 5-year MACE survival for populations with ASCVD or diabetes in the US.

The FDA has extended the review period for palopegteriparatide in treatment of hyperparathyroidism in adult patients by 3 months to August 14, 2024.

Transmasculine patients undergoing GAHT may experience adverse lipid profile changes, unlike transfeminine counterparts, which investigators say is cause for closer monitoring.

A systematic review and meta-analysis of 51 studies suggests elevated Lp(a) can help predict risk of premature atherosclerotic cardiovascular disease.

Boehringer Ingelheim expands access to adalimumab biosimilar adalimumab-adbm through agreement with Quallent Pharmaceuticals,

The SEQUOIA-HCM trial presents aficamten as a promising treatment for symptomatic obstructive hypertrophic cardiomyopathy, showing significant improvements in multiple endpoints.

Nieca Goldberg, MD, discusses important news and updates in cardiovascular health among women from the early portions of 2024.

A Veterans Affairs study finds low alpha-1 antitrypsin phenotyping rates, indicating the need for improved healthcare provider education on AATD.

The latest guidance on hypertrophic cardiomyopathy contain new endorsements for the cardiac myosin inhibitor class and other aspects of management.

Compass Pathways reports positive results for psilocybin in PTSD treatment, showing safety and symptom improvement in an open-label phase 2 study.

A new study highlights the potential of lipoprotein apheresis for reducing cardiovascular events in patients with elevated Lp(a).

Maralixibat oral solution improved pruritus and native liver survival in PFIC patients in the MARCH-PFIC trial.

Geneoscopy's ColoSense received FDA approval on May 06, 2024 based on data from the phase 3 CRC-PREVENT trial.

Data from the ORCA-V trial suggests cytisinicline, a plant-based medication, aids adults in quitting e-cigarettes.

Payal Kohli, MD, discusses how recent advancements have changed conversations surrounding modifiable cardiovascular risk and what it means for practitioners.

The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.